Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Clements

Showing results (441-450 of 462) with videos related to

Pageof 47
Sort By:
Science (New York, N.Y.)|May 23, 1998
AIDS vaccine developmentM Agosto, J Allan, C Benson, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Arthritis and Rheumatism|February 5, 2005
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung StudyDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|March 17, 2006
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna, D E Furst, R D Hays, et al.
The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of AnemiaJohn S Debenham, Christina Madsen-Duggan, Matthew J Clements, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
Pageof 47

Showing results (441-450 of 462) with videos related to

Sort By:
Pageof 47
Science (New York, N.Y.)|May 23, 1998
AIDS vaccine developmentM Agosto, J Allan, C Benson, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Arthritis and Rheumatism|February 5, 2005
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung StudyDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|March 17, 2006
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna, D E Furst, R D Hays, et al.
The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of AnemiaJohn S Debenham, Christina Madsen-Duggan, Matthew J Clements, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
Pageof 47